which has made it a priority of melanoma researchers. Previous research has indicated that MAPK inhibitors could be a potential therapy for NRASMUT melanoma. However, on their own, MAPK inhibitors ...

The lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant ...

[31] Activation of this pathway results in the phosphorylation of MAPK, which then phosphorylates other factors and kinases, ultimately regulating cell survival, proliferation, and differentiation.

As part of The Wistar Institute's Melanoma Research Center, the Villanueva lab pursues new ways to overcome the challenge of melanoma drug resistance. In this paper, the group took aim at melanomas ...

Erasca is a biotech company focused on developing therapies for RAS/MAPK pathway-driven cancers with a strong financial position.

The lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant melanoma: inhibiting the gene S6K2. .

which has made it a priority of melanoma researchers. Previous research has indicated that MAPK inhibitors could be a potential therapy for NRAS MUT melanoma. However, on their own, MAPK ...